联拓生物公布Mavacamten在用于治疗中国患者的EXPLORER-CN III期临床试验中获得积极顶线结果
April 26, 2023 08:00 ET
|
LianBio
Mavacamten在治疗中国有症状的梗阻性肥厚型心肌病患者的研究中达到了主要终点Mavacamten显示出与之前研究结果相一致的安全性特征未来如获批，mavacamten将成为中国首个被批准用于治疗梗阻性肥厚型心肌病的心肌肌球蛋白抑制剂联拓生物将于美国东部时间5月1日（星期一）上午8点/中国时间晚8点召开线上直播会议，就EXPLORER-CN试验的顶线数据及mavacamten在中国的市场机会与...
Pfizer Opts In to LianBio Rights to Respiratory Syncytial Virus Therapeutic Candidate Sisunatovir in Mainland China, Hong Kong, Macau, and Singapore
December 19, 2022 07:00 ET
|
LianBio; Pfizer Inc.
Pfizer will now lead all development and commercialization activities in Mainland China, Hong Kong, Macau, and Singapore LianBio will receive a $20 million upfront payment, to be released from...
LianBio Announces President and Chief Strategy Officer Departure
December 13, 2022 17:00 ET
|
LianBio
SHANGHAI, China and PRINCETON, N.J., Dec. 13, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major...
LianBio Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 10, 2022 16:05 ET
|
LianBio
Enrollment completed in registrational Phase 3 EXPLORER-CN trial of mavacamten, with data expected mid-2023Mavacamten patient education and physician awareness activities underway in China with...
LianBio to Participate in Upcoming Investor and Industry Events
November 10, 2022 08:00 ET
|
LianBio
SHANGHAI, China and PRINCETON, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major...
LianBio Doses First Patient in Phase 1 Trial of BBP-398 in Chinese Patients with Advanced Solid Tumors
November 09, 2022 16:05 ET
|
LianBio
SHANGHAI, China and PRINCETON, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major...
LianBio Doses First Patient in Registrational Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis
November 01, 2022 16:05 ET
|
LianBio
• LIBRA trial designed to support registration in China• Topline results expected in the fourth quarter of 2023 SHANGHAI and PRINCETON, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq:...
LianBio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 11, 2022 16:05 ET
|
LianBio
Completed enrollment in China Phase 3 trial of mavacamten; topline data expected mid-2023 Submitted mavacamten New Drug Application (NDA) in Singapore Submitted infigratinib NDA in Hong Kong Three...
LianBio to Participate in June Investor Events
June 02, 2022 16:02 ET
|
LianBio
SHANGHAI, China and PRINCETON, N.J., June 02, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major...
LianBio Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 12, 2022 08:00 ET
|
LianBio
LianBio’s partner, Bristol Myers Squibb, has received U.S. FDA approval of mavacamten for the treatment of patients with obstructive hypertrophic cardiomyopathy (oHCM) Registrational Phase 3...